Merck KGaA in Talks to Acquire U.S. Cancer Biotech Springworks, Reuters Says, Citing Sources

Dow Jones
10 Feb
 

-- Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources.

-- The deal could be finalized in the comings weeks, if the talks are successful, Reuters reports.

-- Merck KGaA said in a statement that it would continuously assess options and would announce any transactions as and when they materialize, according to Reuters. Springworks declined to comment to Reuters.

Full story: https://bit.ly/40UCAR2

 

Write to Helena Smolak at helena.smolak@wsj.com

 

(END) Dow Jones Newswires

February 10, 2025 10:27 ET (15:27 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10